Engineered immune cells target lupus in early trial
NCT ID NCT07328581
First seen Jan 10, 2026 · Last updated Jun 14, 2026 · Updated 24 times
Summary
This study tests a new treatment called BCMA-CD19-IL-15 cCAR T cells for people with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to attack lupus-causing cells. The goal is to see if it is safe and can reduce disease activity, possibly allowing patients to stop other lupus medications. The study plans to enroll 20 participants aged 16 to 70.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.